Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...
In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...
A new trial from China published in the BMJ journal revealed that telesurgery was non-inferior to standard local robotic ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...
AI mammography detects breast cancers with 6.7% more accuracy and reduces missed cancers by 12%, making breast screening ...
Swiss pharma giant Roche has announced new late-breaking data from the Phase III FENtrepid study showing the investigational ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Telesurgery was as reliable as standard robotic surgery for two common urological procedures, according to a small Chinese ...
The recent presentation of the long-term results of the JCOG0802 phase 3 trial has sparked discussion within the international thoracic surgical community. Initial 5-year results in 2022 reported a ...
Detailed price information for Thiogenesis Therapeutics Corp (TTI-X) from The Globe and Mail including charting and trades.
Find out more about the effectiveness of cast immobilisation versus surgery in treating unimalleolar Weber B ankle fractures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results